omidenepag isopropyl

selective prostaglandin EP2 receptor agonist

Also Known As:

glycine, N-(6-((((4-(1H-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)-, 1-methylethyl ester; isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate

Networked: 27 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Glycine: 5151
    - omidenepag isopropyl: 27
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - omidenepag isopropyl: 27
  - Pyridines: 88
    - omidenepag isopropyl: 27

Experts

1.	Odani-Kawabata, Noriko: 6 articles (11/2021 - 01/2018)
2.	Aihara, Makoto: 5 articles (11/2021 - 01/2019)
3.	Lu, Fenghe: 5 articles (11/2021 - 01/2019)
4.	Iwata, Akihiro: 4 articles (11/2021 - 01/2019)
5.	Kawata, Hisashi: 4 articles (11/2021 - 01/2019)
6.	Nagata, Yuki: 3 articles (01/2021 - 01/2020)
7.	Nakakura, Shunsuke: 3 articles (01/2021 - 01/2020)
8.	Shams, Naveed K: 3 articles (01/2021 - 01/2019)
9.	Inoue, Kenji: 2 articles (01/2022 - 01/2020)
10.	Ishida, Kyoko: 2 articles (01/2022 - 01/2020)

Related Diseases

1.	Ocular Hypertension (Glaucoma, Suspect) 11/01/2021 - "Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study." 01/01/2021 - "A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)." 01/01/2019 - "Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension." 01/01/2022 - "Omidenepag isopropyl (OMDI) is a novel topical ocular hypotensive agent that was launched onto the market for the treatment of glaucoma and ocular hypertension (OHT). " 01/01/2022 - "Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension."
2.	Open-Angle Glaucoma (Glaucoma, Open Angle) 09/01/2022 - "To evaluate omidenepag isopropyl (OMDI) for its efficacy in intraocular pressure control (IOP) and adverse reactions following administrations in Japanese patients with open-angle glaucoma (OAG) over a 3-month period. " 11/01/2021 - "Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study." 01/01/2021 - "A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)." 01/01/2019 - "Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension." 01/01/2021 - "This phase 2, randomized, double-masked, parallel-arm, multicenter study (NCT03858894) was conducted in the United States to examine whether the efficacy and safety of omidenepag isopropyl 0.002% BID dosing was superior to QD dosing in subjects with primary open-angle glaucoma or ocular hypertension. "
3.	Glaucoma 08/09/2023 - "Purpose: To investigate the clinical efficacy of omidenepag isopropyl (OMDI) among glaucoma patients in terms of increased intraocular pressure (IOP) changes through a meta-analysis. " 07/26/2023 - "A 38-year-old woman was diagnosed with left eye glaucoma and prescribed omidenepag isopropyl. " 01/01/2023 - "Omidenepag isopropyl (OMDI) is an intraocular pressure (IOP)-lowering drug used to treat glaucoma. " 01/01/2021 - "We analysed patients with glaucoma who were prescribed topical omidenepag isopropyl from November 2018 to December 2019. " 07/26/2023 - "We report a case of cystoid macular edema development after omidenepag isopropyl use in a patient with glaucoma who had undergone bilateral implantable collamer lens implantation. "
4.	Low Tension Glaucoma 01/01/2020 - "To retrospectively evaluate the short-term efficacy of omidenepag isopropyl (EYBELIS 0.002%) by assessing its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG). " 01/01/2023 - "Influence of 0.002% Omidenepag Isopropyl on Intraocular Pressure and the Cornea in Normal Tension Glaucoma." 01/01/2022 - "Purpose: To retrospectively evaluate the 1-year efficacy and safety of single-agent of omidenepag isopropyl in patients with normal-tension glaucoma (NTG). " 01/01/2022 - "One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma." 01/01/2020 - "Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma."
5.	Exfoliation Syndrome 11/01/2021 - "To assess the long-term safety and efficacy of omidenepag isopropyl (OMDI) 0.002% (a first-in-class, selective, non-prostaglandin, prostanoid EP2 receptor agonist), alone or administered concomitantly with timolol 0.5%, in patients with open-angle glaucoma (OAG, including normal-tension and exfoliation glaucoma) or ocular hypertension (OHT). "

Related Drugs and Biologics

1.	Prostaglandins
2.	Timolol (Blocadren)
3.	prostaglandin F2alpha receptor
4.	Latanoprost (Xalatan)
5.	Ophthalmic Solutions (Eye Drops)
6.	Dinoprostone (PGE2)
7.	Prodrugs
8.	K-115
9.	Carteolol (Carteolol Hydrochloride)
10.	faricimab

Related Therapies and Procedures

1.	Slit Lamp
2.	Lenses
3.	Lasers (Laser)